June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...
June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not using insulin, compared ...
Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...
FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, ...
The CONNECT trial, presented at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans, found that 82% of adults with type 2 diabetes who used a Dexcom G7 improved their blood ...
The FDA gave the green light to Dexcom’s popular over-the-counter glucose monitor Stelo for children 2 years or older who don’t use insulin. (Dexcom) The FDA has given the green light to Dexcom’s ...
AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...
Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer ...
Dexcom has received Food and Drug Administration clearance for the first over-the-counter glucose sensor for children. The ...
DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results